Carnegie Lake Advisors LLC Has $699,000 Stake in Merck & Co., Inc. $MRK

Carnegie Lake Advisors LLC lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,832 shares of the company’s stock after selling 750 shares during the period. Carnegie Lake Advisors LLC’s holdings in Merck & Co., Inc. were worth $699,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Peoples Financial Services CORP. increased its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock worth $1,803,000 after buying an additional 122 shares during the period. McLean Asset Management Corp boosted its position in shares of Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock valued at $292,000 after acquiring an additional 125 shares during the period. Cora Capital Advisors LLC grew its stake in shares of Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock valued at $423,000 after acquiring an additional 125 shares in the last quarter. Saiph Capital LLC increased its position in Merck & Co., Inc. by 3.7% during the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after acquiring an additional 128 shares during the period. Finally, Physician Wealth Advisors Inc. raised its stake in Merck & Co., Inc. by 2.9% in the 2nd quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock worth $363,000 after purchasing an additional 128 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the transaction, the executive vice president directly owned 24,578 shares of the company’s stock, valued at $2,054,475.02. This trade represents a 25.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Wells Fargo & Company lowered their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Citigroup began coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Morgan Stanley upped their price objective on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday, November 3rd. Finally, Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Hold” and a consensus target price of $104.47.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $86.34 on Friday. The company has a market cap of $215.66 billion, a price-to-earnings ratio of 13.30, a PEG ratio of 0.95 and a beta of 0.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The firm has a 50 day simple moving average of $84.59 and a 200 day simple moving average of $82.04. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.22. The company had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.Merck & Co., Inc.’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter last year, the business posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.